Product safety is Paranova’s number one priority
Paranova Group A/S, via its Scandinavian subsidiaries Paranova Danmark A/S, Paranova Läkemedel and Paranova OY, as well as via its German subsidiary EMRAmed by Paranova’s holding company MPA Pharma, have distributed original medicinal products from other EU countries at attractive prices in their home markets in Denmark, Finland, Germany and Sweden for decades. All Paranova and EMRAmed products correspond to those that are distributed by multinational pharmaceuticals companies in Denmark, Finland, Germany and Sweden and are under constant scrutiny by the responsible national Federal Institute for Drugs and Medical Devices. To guarantee the safety and quality of the medicinal products, for years Paranova Group A/S and MPA Pharma have worked closely with trusted suppliers in EU countries and also conducts extensive quality checks before the products are delivered.
Investing in safety and quality
Paranova was established in 1989, in October 2010 Paranova and Germany’s MPA Pharma signed a cooperation agreement. In Germany, the holding company MPA Pharma acquired EMRAmed in 1992 and henceforth managed the business under that name.
In 2010 MPA Pharma invested further in safety and quality by building a modern refrigerated warehouse of 1,000 square metres. Here, large quantities of reimported and parallel imported medicinal products are repackaged, a process during which the cold chain may not be interrupted. The European Commission is currently preparing to introduce even stricter transportation regulations for medicinal products. We are ready to meet the new requirements thanks to our logistics partners who provide us with temperature-controlled transportation services.